Business
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
Dataset grows to more than 312,000 whole genomes with longitudinal clinical dataGSK is one of the first to lead a further expansion of 50,000 whole genomes
About this update from Illumina, Inc.
[{"type":"text","content":"Dataset grows to more than 312,000 whole genomes with longitudinal clinical dataGSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced two advancements in scale and depth of the Alliance for Genomic Discovery (AGD or the Alliance). With the addition of Regeneron Genetics Center® (RGC®) as the tenth member, the Alliance can expand the core dataset to 312,000 whole genomes. The Alliance also announced a new initiative: a dataset of 50,000 additional whole genomes with paired proteomic data generated using Illumina® Protein Prep. GSK is among the first participants in this multiomic expansion.\n \n \n \n \n \n \n \nThe AGD dataset is among the largest collections of whole genome sequences available, and it is the world's largest pairing of whole genome sequences with the depth of clinical data that comes from a leading academic medical center. De-identified, deep phenotypic data from electronic health records (EHR) enables more precise definition of disease cohorts and are enriched for advanced disease.\"AGD has already enabled disease-impacting discoveries in autoimmune disease and obesity, with many more such studies underway, and continued expansion accelerates this progress,\" said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. \"Integrating high-quality clinical and genomic data with advanced AI will help pharma translate discoveries into meaningful advances for patients.\" RGC, a wholly owned subsidiary of Regeneron, harnesses the vast potential of human genetics to discover important new medicines, validate existing research programs, and optimize clinical trials. With a database of nearly 3 million sequenced exomes and de-identified EHRs, RGC enables meaningful biological discoveries and guides Regeneron's broader drug discovery and development efforts.\"We are thrilled to join the Alliance alongside so many of our longtime partners, including Vanderbilt with their exceptional biobank and population-scale genetics program — one of the most impressive in the world,\" said Aris Baras, MD, senior vice president, head of RGC and co-head of Regeneron Genetic Medicines. \"Together, this alliance brings together an extraor...